Nwam LLC purchased a new stake in shares of Corteva (NASDAQ:CTVA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 8,209 shares of the company’s stock, valued at approximately $243,000.
A number of other hedge funds have also recently bought and sold shares of the business. Central Bank & Trust Co. acquired a new position in shares of Corteva during the second quarter worth about $31,000. Atwood & Palmer Inc. acquired a new position in shares of Corteva during the second quarter worth about $33,000. Truewealth LLC acquired a new position in shares of Corteva during the second quarter worth about $36,000. Tompkins Financial Corp acquired a new position in shares of Corteva during the second quarter worth about $44,000. Finally, Quad Cities Investment Group LLC acquired a new position in shares of Corteva during the second quarter worth about $46,000.
Shares of NASDAQ:CTVA traded up $0.40 during trading on Wednesday, hitting $29.53. The company’s stock had a trading volume of 1,515,817 shares, compared to its average volume of 7,014,269. Corteva has a fifty-two week low of $24.35 and a fifty-two week high of $32.00. The firm’s 50-day simple moving average is $27.63.
A number of research analysts have commented on CTVA shares. UBS Group reduced their price objective on Caterpillar from $125.00 to $115.00 and set a “sell” rating on the stock in a research note on Tuesday, June 4th. JPMorgan Chase & Co. set a $44.00 price objective on Charles Schwab and gave the stock a “buy” rating in a research note on Friday, June 21st. Citigroup upgraded Atara Biotherapeutics from a “sell” rating to a “neutral” rating and boosted their price objective for the stock from $23.00 to $24.00 in a research note on Monday, June 3rd. Morgan Stanley cut Meili from an “equal weight” rating to an “underweight” rating and reduced their price objective for the stock from $14.00 to $4.20 in a research note on Monday, June 3rd. Finally, BMO Capital Markets started coverage on Corteva in a research note on Sunday, June 2nd. They set an “outperform” rating and a $37.00 price objective on the stock. One research analyst has rated the stock with a sell rating, ten have given a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $30.79.
In other Corteva news, Director Gregory R. Page purchased 2,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were acquired at an average price of $25.49 per share, for a total transaction of $50,980.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Recommended Story: Why does the United States have a lingering trade deficit?
Want to see what other hedge funds are holding CTVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corteva (NASDAQ:CTVA).
Receive News & Ratings for Corteva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corteva and related companies with MarketBeat.com's FREE daily email newsletter.